BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract. 2009;205:858-862. [PMID: 19679400 DOI: 10.1016/j.prp.2009.07.010] [Cited by in Crossref: 182] [Cited by in F6Publishing: 168] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Strohmeier O, Laßmann S, Riedel B, Mark D, Roth G, Werner M, Zengerle R, von Stetten F. Multiplex genotyping of KRAS point mutations in tumor cell DNA by allele-specific real-time PCR on a centrifugal microfluidic disk segment. Microchim Acta 2014;181:1681-8. [DOI: 10.1007/s00604-013-1099-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
2 Hiraoka K, Inoue T, Taylor RD, Watanabe T, Koshikawa N, Yoda H, Shinohara K, Takatori A, Sugimoto H, Maru Y, Denda T, Fujiwara K, Balmain A, Ozaki T, Bando T, Sugiyama H, Nagase H. Inhibition of KRAS codon 12 mutants using a novel DNA-alkylating pyrrole-imidazole polyamide conjugate. Nat Commun 2015;6:6706. [PMID: 25913614 DOI: 10.1038/ncomms7706] [Cited by in Crossref: 70] [Cited by in F6Publishing: 58] [Article Influence: 10.0] [Reference Citation Analysis]
3 Margonis GA, Kim Y, Spolverato G, Ejaz A, Gupta R, Cosgrove D, Anders R, Karagkounis G, Choti MA, Pawlik TM. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis. JAMA Surg. 2015;150:722-729. [PMID: 26038887 DOI: 10.1001/jamasurg.2015.0313] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 10.0] [Reference Citation Analysis]
4 Wu C, Wang W, Fang L, Su W. Programmable pyrrole-imidazole polyamides: A potent tool for DNA targeting. Chinese Chemical Letters 2018;29:1105-12. [DOI: 10.1016/j.cclet.2018.05.025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
5 Huth L, Jäkel J, Dahl E. Molecular Diagnostic Applications in Colorectal Cancer. Microarrays (Basel) 2014;3:168-79. [PMID: 27600342 DOI: 10.3390/microarrays3030168] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
6 Jauhri M, Bhatnagar A, Gupta S, Bp M, Minhas S, Shokeen Y, Aggarwal S. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study. Tumour Biol. 2017;39:1010428317692265. [PMID: 28222664 DOI: 10.1177/1010428317692265] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
7 Nastasă C, Tamaian R, Oniga O, Tiperciuc B. 5-Arylidene(chromenyl-methylene)-thiazolidinediones: Potential New Agents against Mutant Oncoproteins K-Ras, N-Ras and B-Raf in Colorectal Cancer and Melanoma. Medicina (Kaunas) 2019;55:E85. [PMID: 30935124 DOI: 10.3390/medicina55040085] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
8 He K, Wang Y, Zhong Y, Pan X, Si L, Lu J. KRAS Codon 12 Mutation is Associated with More Aggressive Invasiveness in Synchronous Metastatic Colorectal Cancer (mCRC): Retrospective Research. Onco Targets Ther 2020;13:12601-13. [PMID: 33335401 DOI: 10.2147/OTT.S279312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Modest DP, Camaj P, Heinemann V, Schwarz B, Jung A, Laubender RP, Gamba S, Haertl C, Stintzing S, Primo S, Bruns CJ. KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer. J Cancer Res Clin Oncol 2013;139:953-61. [DOI: 10.1007/s00432-013-1401-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
10 Dócs O, Hegyi K, Mokánszky A, Mónusné A, Beke L, András C, Bedekovics J, Méhes G. Mutant KRAS Status Is Associated with Increased KRAS Copy Number Imbalance: a Potential Mechanism of Molecular Heterogeneity. Pathol Oncol Res 2017;23:417-23. [PMID: 27743339 DOI: 10.1007/s12253-016-0126-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
11 Loong HH, Du N, Cheng C, Lin H, Guo J, Lin G, Li M, Jiang T, Shi Z, Cui Y, Jin X, Yao J, Xing Y, Yao M, Wang K, Mok TSK, Liu L. KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples. Transl Lung Cancer Res 2020;9:1759-69. [PMID: 33209599 DOI: 10.21037/tlcr-20-455] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Stahler A, Heinemann V, Giessen-Jung C, Crispin A, Schalhorn A, Stintzing S, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Quietzsch D, Held S, von Einem JC, Holch J, Neumann J, Kirchner T, Jung A, Modest DP. Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial). Int J Cancer 2016;138:739-46. [PMID: 26284333 DOI: 10.1002/ijc.29807] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
13 Kwon MJ, Lee SE, Kang SY, Choi YL. Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: Comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue. Pathol Res Pract. 2011;207:762-768. [PMID: 22070922 DOI: 10.1016/j.prp.2011.10.002] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
14 Fakih MG, Kopetz S, Kuboki Y, Kim TW, Munster PN, Krauss JC, Falchook GS, Han SW, Heinemann V, Muro K, Strickler JH, Hong DS, Denlinger CS, Girotto G, Lee MA, Henary H, Tran Q, Park JK, Ngarmchamnanrith G, Prenen H, Price TJ. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol 2022;23:115-24. [PMID: 34919824 DOI: 10.1016/S1470-2045(21)00605-7] [Reference Citation Analysis]
15 Mao C, Zhou J, Yang Z, Huang Y, Wu X, Shen H, Tang J, Chen Q. KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer. PLoS One. 2012;7:e36653. [PMID: 22586484 DOI: 10.1371/journal.pone.0036653] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 4.0] [Reference Citation Analysis]
16 Modest DP, Laubender RP, Stintzing S, Giessen C, Schulz C, Haas M, Mansmann U, Heinemann V. Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial. Acta Oncol. 2013;52:956-962. [PMID: 23244709 DOI: 10.3109/0284186x.2012.752580] [Cited by in Crossref: 39] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
17 Ounissi D, Weslati M, Boughriba R, Hazgui M, Bouraoui S. Clinicopathological characteristics and mutational profile of KRAS and NRAS in Tunisian patients with sporadic colorectal cancer. Turk J Med Sci 2021;51:148-58. [PMID: 32892548 DOI: 10.3906/sag-2003-42] [Reference Citation Analysis]
18 Kessler D, Bergner A, Böttcher J, Fischer G, Döbel S, Hinkel M, Müllauer B, Weiss-Puxbaum A, McConnell DB. Drugging all RAS isoforms with one pocket. Future Med Chem 2020;12:1911-23. [PMID: 32779487 DOI: 10.4155/fmc-2020-0221] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
19 Paliogiannis P, Cossu A, Tanda F, Palmieri G, Palomba G. KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma. Oncol Lett 2014;8:1422-6. [PMID: 25202344 DOI: 10.3892/ol.2014.2411] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
20 Arvelo F, Sojo F, Cotte C. Biology of colorectal cancer. Ecancermedicalscience 2015;9:520. [PMID: 25932044 DOI: 10.3332/ecancer.2015.520] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 7.7] [Reference Citation Analysis]
21 Fiala O, Pesek M, Finek J, Benesova L, Belsanova B, Minarik M. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer. Cancer Genetics 2013;206:26-31. [DOI: 10.1016/j.cancergen.2012.12.003] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
22 Park C, Yu Y, Jung H, Jang K, Na S. Detection and discrimination of single nucleotide polymorphisms by exploiting metal ion-mediated DNA duplex. Sensors and Actuators B: Chemical 2020;305:127493. [DOI: 10.1016/j.snb.2019.127493] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
23 Bisht S, Ahmad F, Sawaimoon S, Bhatia S, Das BR. Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma. Med Oncol 2014;31:124. [PMID: 25073438 DOI: 10.1007/s12032-014-0124-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
24 Cabezas-Camarero S, de la Orden García V, García-Barberán V, Mediero-Valeros B, Subhi-Issa AI, Llovet García P, Bando-Polaino I, Merino Menéndez S, Pérez-Segura P, Díaz-Rubio E. Nasoethmoidal Intestinal-Type Adenocarcinoma Treated with Cetuximab: Role of Liquid Biopsy and BEAMing in Predicting Response to Anti-Epidermal Growth Factor Receptor Therapy. Oncologist 2019;24:293-300. [PMID: 30602616 DOI: 10.1634/theoncologist.2018-0387] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Abdul SN, Ab Mutalib NS, Sean KS, Syafruddin SE, Ishak M, Sagap I, Mazlan L, Rose IM, Abu N, Mokhtar NM, Jamal R. Molecular Characterization of Somatic Alterations in Dukes' B and C Colorectal Cancers by Targeted Sequencing. Front Pharmacol 2017;8:465. [PMID: 28769798 DOI: 10.3389/fphar.2017.00465] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
26 Zhang J, Zheng J, Yang Y, Lu J, Gao J, Lu T, Sun J, Jiang H, Zhu Y, Zheng Y, Liang Z, Liu T. Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases. Sci Rep 2015;5:18678. [PMID: 26691448 DOI: 10.1038/srep18678] [Cited by in Crossref: 53] [Cited by in F6Publishing: 63] [Article Influence: 7.6] [Reference Citation Analysis]
27 Stintzing S, Kapaun C, Laubender RP, Jung A, Neumann J, Modest DP, Giessen C, Moosmann N, Wollenberg A, Kirchner T. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer. 2013;132:236-245. [PMID: 22644776 DOI: 10.1002/ijc.27654] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 5.5] [Reference Citation Analysis]
28 Kreutz M, Hochstein N, Kaiser J, Narz F, Peist R. Pyrosequencing: powerful and quantitative sequencing technology. Curr Protoc Mol Biol 2013;104:7.15.1-7.15.23. [PMID: 24510299 DOI: 10.1002/0471142727.mb0715s104] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
29 Zannoni GF, Improta G, Chiarello G, Pettinato A, Petrillo M, Scollo P, Scambia G, Fraggetta F. Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma. Virchows Arch 2014;465:193-8. [PMID: 24889043 DOI: 10.1007/s00428-014-1599-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
30 Heinemann V, Vehling-Kaiser U, Waldschmidt D, Kettner E, Märten A, Winkelmann C, Klein S, Kojouharoff G, Gauler TC, von Weikersthal LF, Clemens MR, Geissler M, Greten TF, Hegewisch-Becker S, Rubanov O, Baake G, Höhler T, Ko YD, Jung A, Neugebauer S, Boeck S. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). Gut 2013;62:751-9. [PMID: 22773551 DOI: 10.1136/gutjnl-2012-302759] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 7.1] [Reference Citation Analysis]
31 Coulson R. Molecular Profiling in Resectable Colorectal Liver Metastases: The Role of KRAS Mutation Status in Assessing Prognosis in the Preoperative Setting. J Adv Pract Oncol 2015;6:470-4. [PMID: 27069739 DOI: 10.6004/jadpro.2015.6.5.7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Neumann JH, Jung A, Kirchner T. [Molecular pathology of colorectal cancer]. Pathologe 2015;36:137-44. [PMID: 25777075 DOI: 10.1007/s00292-015-0005-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
33 Xie G, Xie F, Wu P, Yuan X, Ma Y, Xu Y, Li L, Xu L, Yang M, Shen L. The mutation rates of EGFR in non-small cell lung cancer and KRAS in colorectal cancer of Chinese patients as detected by pyrosequencing using a novel dispensation order. J Exp Clin Cancer Res 2015;34:63. [PMID: 26081767 DOI: 10.1186/s13046-015-0179-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
34 Ozen F, Ozdemir S, Zemheri E, Hacimuto G, Silan F, Ozdemir O. The proto-oncogene KRAS and BRAF profiles and some clinical characteristics in colorectal cancer in the Turkish population. Genet Test Mol Biomarkers 2013;17:135-9. [PMID: 23297805 DOI: 10.1089/gtmb.2012.0290] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
35 Fiala O, Buchler T, Mohelnikova-Duchonova B, Melichar B, Matejka VM, Holubec L, Kulhankova J, Bortlicek Z, Bartouskova M, Liska V, Topolcan O, Sedivcova M, Finek J. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. Tumour Biol 2016;37:6823-30. [PMID: 26662311 DOI: 10.1007/s13277-015-4523-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
36 Morandi L, de Biase D, Visani M, Cesari V, De Maglio G, Pizzolitto S, Pession A, Tallini G. Allele specific locked nucleic acid quantitative PCR (ASLNAqPCR): an accurate and cost-effective assay to diagnose and quantify KRAS and BRAF mutation. PLoS One 2012;7:e36084. [PMID: 22558339 DOI: 10.1371/journal.pone.0036084] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 4.2] [Reference Citation Analysis]
37 Hayama T, Hashiguchi Y, Okamoto K, Okada Y, Ono K, Shimada R, Ozawa T, Toyoda T, Tsuchiya T, Iinuma H, Nozawa K, Matsuda K. G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer. Int J Colorectal Dis 2019;34:1491-6. [PMID: 31309326 DOI: 10.1007/s00384-019-03344-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
38 Seol YM, Kwon CH, Lee SJ, Lee SJ, Choi Y, Choi YJ, Kim H, Park DY. A Pilot Prospective Study of Refractory Solid Tumor Patients for NGS-Based Targeted Anticancer Therapy. Transl Oncol 2019;12:301-7. [PMID: 30448735 DOI: 10.1016/j.tranon.2018.10.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
39 Lin Z, Liu Y, Cai S, Yang C, Zhou L, Li W. Not All Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations Predict Poor Survival in Patients With Unresectable Colorectal Liver Metastasis. Technol Cancer Res Treat 2021;20:15330338211039131. [PMID: 34669528 DOI: 10.1177/15330338211039131] [Reference Citation Analysis]
40 Kriegl L, Neumann J, Vieth M, Greten FR, Reu S, Jung A, Kirchner T. Up and downregulation of p16Ink4a expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer. Mod Pathol 2011;24:1015-22. [DOI: 10.1038/modpathol.2011.43] [Cited by in Crossref: 68] [Cited by in F6Publishing: 67] [Article Influence: 6.2] [Reference Citation Analysis]
41 Mao W, Zhou J, Zhang H, Qiu L, Tan H, Hu Y, Shi H. Relationship between KRAS mutations and dual time point <sup>18</sup>F-FDG PET/CT imaging in colorectal liver metastases. Abdom Radiol (NY). 2019;44:2059-2066. [PMID: 30143816 DOI: 10.1007/s00261-018-1740-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
42 Kim YJ, Chambers AG, Cecchi F, Hembrough T. Targeted data-independent acquisition for mass spectrometric detection of RAS mutations in formalin-fixed, paraffin-embedded tumor biopsies. Journal of Proteomics 2018;189:91-6. [DOI: 10.1016/j.jprot.2018.04.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
43 Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Chan E, Nair S, Berenberg JL, McWilliams RR; Alliance for Clinical Trials in Oncology. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst 2014;106:dju106. [PMID: 24925349 DOI: 10.1093/jnci/dju106] [Cited by in Crossref: 90] [Cited by in F6Publishing: 89] [Article Influence: 11.3] [Reference Citation Analysis]
44 Jurmeister P, Vollbrecht C, Behnke A, Frost N, Arnold A, Treue D, Rückert JC, Neudecker J, Schweizer L, Klauschen F, Horst D, Hummel M, Dietel M, von Laffert M. Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic options. Lung Cancer 2019;138:43-51. [PMID: 31634654 DOI: 10.1016/j.lungcan.2019.10.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
45 Tawfeeq N, Jin Y, Lamango NS. Synthetic Optimization and MAPK Pathway Activation Anticancer Mechanism of Polyisoprenylated Cysteinyl Amide Inhibitors. Cancers (Basel) 2021;13:5757. [PMID: 34830912 DOI: 10.3390/cancers13225757] [Reference Citation Analysis]
46 Mancini I, Santucci C, Sestini R, Simi L, Pratesi N, Cianchi F, Valanzano R, Pinzani P, Orlando C. The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer. J Mol Diagn 2010;12:705-11. [PMID: 20616366 DOI: 10.2353/jmoldx.2010.100018] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 4.3] [Reference Citation Analysis]
47 Lamy A, Blanchard F, Le Pessot F, Sesboüé R, Di Fiore F, Bossut J, Fiant E, Frébourg T, Sabourin JC. Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls. Mod Pathol 2011;24:1090-100. [PMID: 21516079 DOI: 10.1038/modpathol.2011.60] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 5.9] [Reference Citation Analysis]
48 Tripathi S, Belkacemi L, Cheung MS, Bose RN. Correlation between Gene Variants, Signaling Pathways, and Efficacy of Chemotherapy Drugs against Colon Cancers. Cancer Inform 2016;15:1-13. [PMID: 26819545 DOI: 10.4137/CIN.S34506] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
49 Patankar M, Eskelinen S, Tuomisto A, Mäkinen MJ, Karttunen TJ. KRAS and BRAF mutations induce anoikis resistance and characteristic 3D phenotypes in Caco‑2 cells. Mol Med Rep 2019;20:4634-44. [PMID: 31545494 DOI: 10.3892/mmr.2019.10693] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
50 Neumann J, Wehweck L, Maatz S, Engel J, Kirchner T, Jung A. Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis. Virchows Arch 2013;463:509-23. [DOI: 10.1007/s00428-013-1450-0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
51 Westwood M, van Asselt T, Ramaekers B, Whiting P, Joore M, Armstrong N, Noake C, Ross J, Severens J, Kleijnen J. KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis. Health Technol Assess 2014;18:1-132. [PMID: 25314637 DOI: 10.3310/hta18620] [Cited by in Crossref: 51] [Cited by in F6Publishing: 38] [Article Influence: 7.3] [Reference Citation Analysis]
52 Li B, Jiang Y, Chen X, Ellington AD. Probing spatial organization of DNA strands using enzyme-free hairpin assembly circuits. J Am Chem Soc 2012;134:13918-21. [PMID: 22894754 DOI: 10.1021/ja300984b] [Cited by in Crossref: 177] [Cited by in F6Publishing: 166] [Article Influence: 17.7] [Reference Citation Analysis]
53 Macedo MP, Andrade Lde B, Coudry R, Crespo R, Gomes M, Lisboa BC, Aguiar S, Soares FA, Carraro DM, Cunha IW. Multiple mutations in the Kras gene in colorectal cancer: review of the literature with two case reports. Int J Colorectal Dis. 2011;26:1241-1248. [PMID: 21603900 DOI: 10.1007/s00384-011-1238-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
54 Withers J, Padroni G, Pauff S, Clark A, Mackay S, Burley G. DNA Minor Groove Binders as Therapeutic Agents. Comprehensive Supramolecular Chemistry II. Elsevier; 2017. pp. 149-78. [DOI: 10.1016/b978-0-12-409547-2.12561-2] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
55 Schäfer C, Seeliger H, Bader DC, Assmann G, Buchner D, Guo Y, Ziesch A, Palagyi A, Ochs S, Laubender RP. Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. J Cell Mol Med. 2012;16:1776-1791. [PMID: 22004109 DOI: 10.1111/j.1582-4934.2011.01473.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
56 Hamidi H, Lu M, Chau K, Anderson L, Fejzo M, Ginther C, Linnartz R, Zubel A, Slamon DJ, Finn RS. KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition. Br J Cancer 2014;111:1788-801. [PMID: 25167228 DOI: 10.1038/bjc.2014.475] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
57 Cottrell CE, Al-Kateb H, Bredemeyer AJ, Duncavage EJ, Spencer DH, Abel HJ, Lockwood CM, Hagemann IS, O'Guin SM, Burcea LC, Sawyer CS, Oschwald DM, Stratman JL, Sher DA, Johnson MR, Brown JT, Cliften PF, George B, McIntosh LD, Shrivastava S, Nguyen TT, Payton JE, Watson MA, Crosby SD, Head RD, Mitra RD, Nagarajan R, Kulkarni S, Seibert K, Virgin HW 4th, Milbrandt J, Pfeifer JD. Validation of a next-generation sequencing assay for clinical molecular oncology. J Mol Diagn 2014;16:89-105. [PMID: 24211365 DOI: 10.1016/j.jmoldx.2013.10.002] [Cited by in Crossref: 148] [Cited by in F6Publishing: 122] [Article Influence: 16.4] [Reference Citation Analysis]
58 Koçer NE, Kayaselçuk F. Is availability of anti-EGFR therapy for the colorectal adenocarcinomas showing fascin expression limited? Target Oncol 2014;9:171-5. [PMID: 23588415 DOI: 10.1007/s11523-013-0275-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
59 Dijkstra JR, Opdam FJ, Boonyaratanakornkit J, Schönbrunner ER, Shahbazian M, Edsjö A, Hoefler G, Jung A, Kotsinas A, Gorgoulis VG, López-Ríos F, de Stricker K, Rouleau E, Biesmans B, van Krieken JH. Implementation of formalin-fixed, paraffin-embedded cell line pellets as high-quality process controls in quality assessment programs for KRAS mutation analysis. J Mol Diagn 2012;14:187-91. [PMID: 22414609 DOI: 10.1016/j.jmoldx.2012.01.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
60 Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, Stintzing S, Graeven U, Arnold D, von Weikersthal LF, Giessen-Jung C, Stahler A, Schmoll HJ, Jung A, Kirchner T, Tannapfel A, Reinacher-Schick A. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Ann Oncol 2016;27:1746-53. [PMID: 27358379 DOI: 10.1093/annonc/mdw261] [Cited by in Crossref: 101] [Cited by in F6Publishing: 92] [Article Influence: 16.8] [Reference Citation Analysis]
61 Hasbullah HH, Musa M. Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward? Int J Mol Sci 2021;22:11941. [PMID: 34769370 DOI: 10.3390/ijms222111941] [Reference Citation Analysis]
62 Ofir Dovrat T, Sokol E, Frampton G, Shachar E, Pelles S, Geva R, Wolf I. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations. Cancer Biol Ther 2018;19:871-4. [PMID: 30036146 DOI: 10.1080/15384047.2018.1480289] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
63 Nguyen HT, Duong HQ. The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy (review). Oncol Lett. 2018;16:9-18. [PMID: 29928381 DOI: 10.3892/ol.2018.8679] [Cited by in Crossref: 31] [Cited by in F6Publishing: 50] [Article Influence: 7.8] [Reference Citation Analysis]
64 Jones RP, Brudvik KW, Franklin JM, Poston GJ. Precision surgery for colorectal liver metastases: Opportunities and challenges of omics-based decision making. Eur J Surg Oncol. 2017;43:875-883. [PMID: 28302330 DOI: 10.1016/j.ejso.2017.02.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
65 Sterk C, Gräber L, Schmitz HP, Heinisch JJ. Analysis of Functional Domains in Rho5, the Yeast Homolog of Human Rac1 GTPase, in Oxidative Stress Response. Int J Mol Sci 2019;20:E5550. [PMID: 31703278 DOI: 10.3390/ijms20225550] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
66 Delord JP, Tabernero J, García-Carbonero R, Cervantes A, Gomez-Roca C, Bergé Y, Capdevila J, Paz-Ares L, Roda D, Delmar P, Oppenheim D, Brossard SS, Farzaneh F, Manenti L, Passioukov A, Ott MG, Soria JC. Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. Eur J Cancer 2014;50:496-505. [PMID: 24262587 DOI: 10.1016/j.ejca.2013.10.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
67 Ning W, Yang Z, Kocher GJ, Dorn P, Peng R. A Breakthrough Brought about by Targeting KRASG12C: Nonconformity Is Punished. Cancers 2022;14:390. [DOI: 10.3390/cancers14020390] [Reference Citation Analysis]
68 Danysh BP, Rieger EY, Sinha DK, Evers CV, Cote GJ, Cabanillas ME, Hofmann MC. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. Oncotarget 2016;7:30907-23. [PMID: 27127178 DOI: 10.18632/oncotarget.9023] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
69 Xie F, Huang J, Qu S, Wu W, Jiang J, Wang H, Wang S, Liu Q, Zhang S, Xu L, Gao S, Zhang Y, Zhao J, Chen W. Sensitive detection of trace amounts of KRAS codon 12 mutations by a fast and novel one-step technique. Clin Biochem 2014;47:237-42. [PMID: 25192863 DOI: 10.1016/j.clinbiochem.2014.08.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
70 Brotto K, Malisic E, Cavic M, Krivokuca A, Jankovic R. The Usability of Allele-Specific PCR and Reverse-Hybridization Assays for KRAS Genotyping in Serbian Colorectal Cancer Patients. Dig Dis Sci 2013;58:998-1003. [DOI: 10.1007/s10620-012-2469-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
71 Zlobec I, Kovac M, Erzberger P, Molinari F, Bihl MP, Rufle A, Foerster A, Frattini M, Terracciano L, Heinimann K. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer. Int J Cancer. 2010;127:2569-2575. [PMID: 20162668 DOI: 10.1002/ijc.25265] [Cited by in Crossref: 79] [Cited by in F6Publishing: 58] [Article Influence: 6.6] [Reference Citation Analysis]
72 Wang C, Fakih M. Targeting KRAS in Colorectal Cancer. Curr Oncol Rep 2021;23:28. [PMID: 33582927 DOI: 10.1007/s11912-021-01022-0] [Reference Citation Analysis]
73 Kodaz H, Hacibekiroglu I, Erdogan B, Turkmen E, Tozkir H, Albayrak D, Uzunoglu S, Cicin I. Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors. Mol Clin Oncol 2015;3:179-84. [PMID: 25469291 DOI: 10.3892/mco.2014.448] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
74 Sun Q, Pastor L, Du J, Powell MJ, Zhang A, Bodmer W, Wu J, Zheng S, Sha MY. A novel xenonucleic acid-mediated molecular clamping technology for early colorectal cancer screening. PLoS One 2021;16:e0244332. [PMID: 34610014 DOI: 10.1371/journal.pone.0244332] [Reference Citation Analysis]
75 Bai B, Shan L, Xie B, Huang X, Mao W, Wang X, Wang D, Zhu H. Mutations in KRAS codon 12 predict poor survival in Chinese patients with metastatic colorectal cancer. Oncol Lett 2018;15:3161-6. [PMID: 29435051 DOI: 10.3892/ol.2017.7709] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
76 Shen Y, Wang J, Han X, Yang H, Wang S, Lin D, Shi Y. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PLoS One. 2013;8:e81628. [PMID: 24339949 DOI: 10.1371/journal.pone.0081628] [Cited by in Crossref: 58] [Cited by in F6Publishing: 63] [Article Influence: 6.4] [Reference Citation Analysis]
77 Reid GG, Bin Yameen TA, Parker JL. Impact of biomarkers on clinical trial risk. Pharmacogenomics 2013;14:1645-58. [PMID: 24088135 DOI: 10.2217/pgs.13.167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
78 Fisher KW, Lopez-Beltran A, Montironi R, Cheng L. Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus. Future Oncol 2015;11:2711-9. [PMID: 26338658 DOI: 10.2217/fon.15.219] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
79 Lou E, D'Souza D, Nelson AC. Therapeutic Response of Metastatic Colorectal Cancer Harboring a KRAS Missense Mutation After Combination Chemotherapy With the EGFR Inhibitor Panitumumab. J Natl Compr Canc Netw. 2017;15:427-432. [PMID: 28404754 DOI: 10.6004/jnccn.2017.0043] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
80 Ibrahim T, Saer-Ghorra C, Trak-Smayra V, Nadiri S, Yazbeck C, Baz M, Kattan JG. Molecular characteristics of colorectal cancer in a Middle Eastern population in a single institution. Ann Saudi Med 2018;38:251-9. [PMID: 30078023 DOI: 10.5144/0256-4947.2018.251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
81 Valentini P, Fiammengo R, Sabella S, Gariboldi M, Maiorano G, Cingolani R, Pompa PP. Gold-Nanoparticle-Based Colorimetric Discrimination of Cancer-Related Point Mutations with Picomolar Sensitivity. ACS Nano 2013;7:5530-8. [DOI: 10.1021/nn401757w] [Cited by in Crossref: 84] [Cited by in F6Publishing: 72] [Article Influence: 9.3] [Reference Citation Analysis]
82 Herreros-Villanueva M, Chen CC, Yuan SS, Liu TC, Er TK. KRAS mutations: analytical considerations. Clin Chim Acta 2014;431:211-20. [PMID: 24534449 DOI: 10.1016/j.cca.2014.01.049] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
83 Malapelle U, Passiglia F, Cremolini C, Reale ML, Pepe F, Pisapia P, Avallone A, Cortinovis D, De Stefano A, Fassan M, Fontanini G, Galetta D, Lauricella C, Listì A, Loupakis F, Pagni F, Pietrantonio F, Pilotto S, Righi L, Bianchi AS, Parra HS, Tiseo M, Verzè M, Troncone G, Novello S. RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. Eur J Cancer 2021;146:74-83. [PMID: 33588147 DOI: 10.1016/j.ejca.2021.01.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
84 Chen CC, Er TK, Liu YY, Hwang JK, Barrio MJ, Rodrigo M, Garcia-Toro E, Herreros-Villanueva M. Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations. PLoS One 2013;8:e55793. [PMID: 23437064 DOI: 10.1371/journal.pone.0055793] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.1] [Reference Citation Analysis]
85 Lee TH, Park E, Goh YG, Lee HB, Rou WS, Eun HS. The Specific Gravity-Free Method for the Isolation of Circulating Tumor KRAS Mutant DNA and Exosome in Colorectal Cancer. Micromachines (Basel) 2021;12:987. [PMID: 34442609 DOI: 10.3390/mi12080987] [Reference Citation Analysis]
86 Kessler D, Gmachl M, Mantoulidis A, Martin LJ, Zoephel A, Mayer M, Gollner A, Covini D, Fischer S, Gerstberger T, Gmaschitz T, Goodwin C, Greb P, Häring D, Hela W, Hoffmann J, Karolyi-Oezguer J, Knesl P, Kornigg S, Koegl M, Kousek R, Lamarre L, Moser F, Munico-Martinez S, Peinsipp C, Phan J, Rinnenthal J, Sai J, Salamon C, Scherbantin Y, Schipany K, Schnitzer R, Schrenk A, Sharps B, Siszler G, Sun Q, Waterson A, Wolkerstorfer B, Zeeb M, Pearson M, Fesik SW, McConnell DB. Drugging an undruggable pocket on KRAS. Proc Natl Acad Sci U S A 2019;116:15823-9. [PMID: 31332011 DOI: 10.1073/pnas.1904529116] [Cited by in Crossref: 112] [Cited by in F6Publishing: 106] [Article Influence: 37.3] [Reference Citation Analysis]
87 Lehmann A, Schewe C, Hennig G, Denkert C, Weichert W, Budczies J, Dietel M. Applicability of a System for Fully Automated Nucleic Acid Extraction From Formalin-fixed Paraffin-embedded Sections for Routine KRAS Mutation Testing: . Diagnostic Molecular Pathology 2012;21:114-9. [DOI: 10.1097/pdm.0b013e31823569ca] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
88 Modest DP, Brodowicz T, Stintzing S, Jung A, Neumann J, Laubender RP, Ocvirk J, Kurteva G, Papai Z, Knittelfelder R. Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials. Oncology. 2012;83:241-247. [PMID: 22948721 DOI: 10.1159/000339534] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
89 Jones RP, Sutton PA, Evans JP, Clifford R, McAvoy A, Lewis J, Rousseau A, Mountford R, McWhirter D, Malik HZ. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. Br J Cancer. 2017;116:923-929. [PMID: 28208157 DOI: 10.1038/bjc.2017.37] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 9.8] [Reference Citation Analysis]
90 Schuck RN, Marek E, Rogers H, Pacanowski M. Clinical and regulatory considerations in pharmacogenetic testing. Am J Health Syst Pharm 2016;73:1999-2006. [PMID: 27864207 DOI: 10.2146/ajhp160476] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
91 Steinestel K, Brüderlein S, Steinestel J, Märkl B, Schwerer MJ, Arndt A, Kraft K, Pröpper C, Möller P. Expression of Abelson interactor 1 (Abi1) correlates with inflammation, KRAS mutation and adenomatous change during colonic carcinogenesis. PLoS One 2012;7:e40671. [PMID: 22808230 DOI: 10.1371/journal.pone.0040671] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
92 Patil H, Korde R, Kapat A. KRAS gene mutations in correlation with clinicopathological features of colorectal carcinomas in Indian patient cohort. Med Oncol 2013;30. [DOI: 10.1007/s12032-013-0617-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
93 Milanesi E, Dobre M, Bucuroiu AI, Herlea V, Manuc TE, Salvi A, De Petro G, Manuc M, Becheanu G. miRNAs-Based Molecular Signature for KRAS Mutated and Wild Type Colorectal Cancer: An Explorative Study. J Immunol Res 2020;2020:4927120. [PMID: 32676506 DOI: 10.1155/2020/4927120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
94 Khrenova MG, Kulakova AM, Nemukhin AV. Proof of concept for poor inhibitor binding and efficient formation of covalent adducts of KRASG12C and ARS compounds. Org Biomol Chem 2020;18:3069-81. [PMID: 32101243 DOI: 10.1039/d0ob00071j] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 4.5] [Reference Citation Analysis]
95 Hao YX, Li YM, Ye M, Guo YY, Li QW, Peng XM, Wang Q, Zhang SF, Zhao HX, Zhang H, Li GH, Zhu JH, Xiao WH. KRAS and BRAF mutations in serum exosomes from patients with colorectal cancer in a Chinese population. Oncol Lett 2017;13:3608-16. [PMID: 28521461 DOI: 10.3892/ol.2017.5889] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
96 Wang QL, Zhou CL, Yin YF, Xiao L, Wang Y, Li K. An enzymatic on/off switch-mediated assay for KRAS hotspot point mutation detection of circulating tumor DNA. J Clin Lab Anal 2020;34:e23305. [PMID: 32207862 DOI: 10.1002/jcla.23305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
97 Modest DP, Reinacher-Schick A, Stintzing S, Giessen C, Tannapfel A, Laubender RP, Brodowicz T, Knittelfelder R, Vrbanec D, Schmiegel W, Heinemann V, Zielinski CC. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis. Anticancer Drugs 2012;23:666-73. [PMID: 22441566 DOI: 10.1097/CAD.0b013e328352ff1d] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
98 Tierling S, Sers C, Lehmann A, Walter J. A fast, cost-efficient and sensitive approach for KRAS mutation detection using multiplexed primer extension with IP/RP-HPLC separation. Int J Cancer 2012;130:567-74. [PMID: 21387306 DOI: 10.1002/ijc.26040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
99 Nguyen HT, Le DT, Duong QH, Tatipamula VB, Van Nguyen B. High frequency of microsatellite instability and its substantial co-existence with KRAS and BRAF mutations in Vietnamese patients with colorectal cancer. Oncol Lett 2021;21:41. [PMID: 33262833 DOI: 10.3892/ol.2020.12302] [Reference Citation Analysis]
100 Pérez-Ruiz E, Rueda A, Pereda T, Alcaide J, Bautista D, Rivas-Ruiz F, Villatoro R, Pérez D, Redondo M. Involvement of K-RAS mutations and amino acid substitutions in the survival of metastatic colorectal cancer patients. Tumour Biol. 2012;33:1829-1835. [PMID: 22791568 DOI: 10.1007/s13277-012-0442-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
101 Angelucci A, Delle Monache S, Cortellini A, Di Padova M, Ficorella C. "Vessels in the Storm": Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer. Int J Mol Sci 2018;19:E299. [PMID: 29351242 DOI: 10.3390/ijms19010299] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
102 Gotea V, Gartner JJ, Qutob N, Elnitski L, Samuels Y. The functional relevance of somatic synonymous mutations in melanoma and other cancers. Pigment Cell Melanoma Res 2015;28:673-84. [PMID: 26300548 DOI: 10.1111/pcmr.12413] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
103 Nagasaka M, Li Y, Sukari A, Ou SI, Al-Hallak MN, Azmi AS. KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?Cancer Treat Rev. 2020;84:101974. [PMID: 32014824 DOI: 10.1016/j.ctrv.2020.101974] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 29.0] [Reference Citation Analysis]
104 Sundström M, Edlund K, Lindell M, Glimelius B, Birgisson H, Micke P, Botling J. KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice. BMC Cancer. 2010;10:660. [PMID: 21122130 DOI: 10.1186/1471-2407-10-660] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 4.0] [Reference Citation Analysis]
105 Yu C, Luo D, Yu J, Zhang M, Zheng X, Xu G, Wang J, Wang H, Xu Y, Jiang K, Xu J, Ma X, Jing J, Shi H. Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer. Oncogene 2021. [PMID: 34718347 DOI: 10.1038/s41388-021-02077-w] [Reference Citation Analysis]
106 Modest D, Jung A, Moosmann N, Laubender R, Giessen C, Schulz C, Haas M, Neumann J, Boeck S, Kirchner T, Heinemann V, Stintzing S. The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: An analysis of the AIO KRK-0104-trial. Int J Cancer 2012;131:980-6. [DOI: 10.1002/ijc.26467] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
107 Margonis GA, Kreis ME, Wolfgang CL, Weiss MJ. Mutation status and surgical selection. J Surg Oncol 2019;119:616-22. [PMID: 30779134 DOI: 10.1002/jso.25413] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
108 Dumur CI, Idowu MO, Powers CN. Targeting tyrosine kinases in cancer: the converging roles of cytopathology and molecular pathology in the era of genomic medicine. Cancer Cytopathol 2013;121:61-71. [PMID: 22887782 DOI: 10.1002/cncy.21225] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
109 Gamba S, Camaj P, Heinemann V, Laubender RP, Wang Y, Zhao Y, Stintzing S, Giessen C, Boeck S, Haertl C, Bruns CJ, Modest DP. Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib. Anticancer Drugs 2015;26:371-8. [PMID: 25514114 DOI: 10.1097/CAD.0000000000000196] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
110 Pang SW, Awi NJ, Armon S, Lim WW, Low JS, Peh KB, Peh SC, Teow SY. Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC). Diagnostics (Basel) 2019;10:E9. [PMID: 31877940 DOI: 10.3390/diagnostics10010009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
111 Giannelli SM, Mcphaul L, Nakamoto J, Gianoukakis AG. Familial Adenomatous Polyposis–Associated, Cribriform Morular Variant of Papillary Thyroid Carcinoma Harboring a K-RAS Mutation: Case Presentation and Review of Molecular Mechanisms. Thyroid 2014;24:1184-9. [DOI: 10.1089/thy.2013.0589] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
112 Moreno-Manuel A, Calabuig-Fariñas S, Obrador-Hevia A, Blasco A, Fernández-Díaz A, Sirera R, Camps C, Jantus-Lewintre E. dPCR application in liquid biopsies: divide and conquer. Expert Rev Mol Diagn 2021;21:3-15. [PMID: 33305634 DOI: 10.1080/14737159.2021.1860759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
113 Cherri S, Libertini M, Zaniboni A. New drugs for the treatment of metastatic colorectal cancer. World J Gastrointest Oncol 2021; 13(11): 1551-1560 [PMID: 34853636 DOI: 10.4251/wjgo.v13.i11.1551] [Reference Citation Analysis]
114 Taylor RD, Chandran A, Kashiwazaki G, Hashiya K, Bando T, Nagase H, Sugiyama H. Selective Targeting of the KRAS Codon 12 Mutation Sequence by Pyrrole-Imidazole Polyamide seco -CBI Conjugates. Chem Eur J 2015;21:14996-5003. [DOI: 10.1002/chem.201501870] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
115 Kim JH. PCR free multiple ligase reactions and probe cleavages for the SNP detection of KRAS mutation with attomole sensitivity. Analyst 2016;141:6381-6. [DOI: 10.1039/c6an00909c] [Cited by in Crossref: 7] [Article Influence: 1.2] [Reference Citation Analysis]
116 Zahrani A, Kandil M, Badar T, Abdelsalam M, Al-faiar A, Ismail A. Clinico-pathological Study of K-ras Mutations in Colorectal Tumors in Saudi Arabia. Tumori Journal 2018;100:75-9. [DOI: 10.1177/1430.15819] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
117 Modest DP, Stintzing S, Laubender RP, Neumann J, Jung A, Giessen C, Haas M, Aubele P, Schulz C, Boeck S, Stemmler HJ, Kirchner T, Heinemann V. Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status. Anticancer Drugs 2011;22:913-8. [PMID: 21795973 DOI: 10.1097/CAD.0b013e3283493160] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
118 Zhou Y, Zhao J, Fang J, Martin W, Li L, Nussinov R, Chan TA, Eng C, Cheng F. My personal mutanome: a computational genomic medicine platform for searching network perturbing alleles linking genotype to phenotype. Genome Biol 2021;22:53. [PMID: 33514395 DOI: 10.1186/s13059-021-02269-3] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
119 Deschoolmeester V, Boeckx C, Baay M, Weyler J, Wuyts W, Van Marck E, Peeters M, Lardon F, Vermorken JB. KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis. Br J Cancer 2010;103:1627-36. [PMID: 20959826 DOI: 10.1038/sj.bjc.6605959] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
120 Mathieu M, Steier V, Fassy F, Delorme C, Papin D, Genet B, Duffieux F, Bertrand T, Delarbre L, Le-Borgne H, Parent A, Didier P, Marquette JP, Lowinski M, Houtmann J, Lamberton A, Debussche L, Alexey R. KRAS G12C fragment screening renders new binding pockets. Small GTPases 2021;:1-14. [PMID: 34558391 DOI: 10.1080/21541248.2021.1979360] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
121 Camaj P, Primo S, Wang Y, Heinemann V, Zhao Y, Laubender RP, Stintzing S, Giessen-jung C, Jung A, Gamba S, Bruns CJ, Modest DP. KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer. Future Oncology 2015;11:1919-29. [DOI: 10.2217/fon.15.97] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
122 Nagasaka M, Potugari B, Nguyen A, Sukari A, Azmi AS, Ou SI. KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond. Cancer Treat Rev 2021;101:102309. [PMID: 34715449 DOI: 10.1016/j.ctrv.2021.102309] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Orue A, Rieber M. Optimized Multiplex Detection of 7 KRAS Mutations by Taqman Allele-Specific qPCR. PLoS One 2016;11:e0163070. [PMID: 27632281 DOI: 10.1371/journal.pone.0163070] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
124 Bala P, Singh AK, Kavadipula P, Kotapalli V, Sabarinathan R, Bashyam MD. Exome sequencing identifies ARID2 as a novel tumor suppressor in early-onset sporadic rectal cancer. Oncogene 2021;40:863-74. [PMID: 33262464 DOI: 10.1038/s41388-020-01537-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
125 Marchoudi N, Amrani Hassani Joutei H, Jouali F, Fekkak J, Rhaissi H. Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer. Pathol Biol (Paris) 2013;61:273-6. [PMID: 23849768 DOI: 10.1016/j.patbio.2013.05.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
126 Ciardiello F, Tejpar S, Normanno N, Mercadante D, Teague T, Wohlschlegel B, Van Cutsem E. Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia. Target Oncol 2011;6:133-45. [PMID: 21630045 DOI: 10.1007/s11523-011-0181-x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
127 Boeck S, Jung A, Laubender RP, Neumann J, Egg R, Goritschan C, Vehling-Kaiser U, Winkelmann C, Fischer von Weikersthal L, Clemens MR. EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. Br J Cancer. 2013;108:469-476. [PMID: 23169292 DOI: 10.1038/bjc.2012.495] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 6.0] [Reference Citation Analysis]
128 Brait M, Izumchenko E, Kagohara LT, Long S, Wysocki PT, Faherty B, Fertig EJ, Khor TO, Bruckheimer E, Baia G, Ciznadija D, Sloma I, Ben-Zvi I, Paz K, Sidransky D. Comparative mutational landscape analysis of patient-derived tumour xenografts. Br J Cancer 2017;116:515-23. [PMID: 28118322 DOI: 10.1038/bjc.2016.450] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
129 Sui X, Chen Y, Liu B, Li L, Huang X, Wang M, Wang G, Gao X, Zhang L, Bao X, Yang D, Wang X, Zhong C. The relationship between KRAS gene mutation and intestinal flora in tumor tissues of colorectal cancer patients. Ann Transl Med 2020;8:1085. [PMID: 33145304 DOI: 10.21037/atm-20-5622] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
130 Dimmler A, Geddert H, Faller G. EGFR, KRAS, BRAF-mutations and microsatellite instability are absent in goblet cell carcinoids of the appendix. Pathology - Research and Practice 2014;210:274-8. [DOI: 10.1016/j.prp.2014.01.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
131 Kriegl L, Jung A, Horst D, Rizzani A, Jackstadt R, Hermeking H, Gallmeier E, Gerbes AL, Kirchner T, Göke B, De Toni EN. Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer. PLoS One 2012;7:e51654. [PMID: 23284732 DOI: 10.1371/journal.pone.0051654] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
132 Kun EHS, Tsang YTM, Lin S, Pan S, Medapalli T, Malpica A, Richards JS, Gershenson DM, Wong KK. Differences in gynecologic tumor development in Amhr2-Cre mice with KRASG12D or KRASG12V mutations. Sci Rep 2020;10:20678. [PMID: 33244099 DOI: 10.1038/s41598-020-77666-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
133 Yang Q, Schmidt J, Soucy G, Odze R, Dejesa-jamanila L, Arnold K, Kuslich C, Lash R. KRAS mutational status of endoscopic biopsies matches resection specimens. J Clin Pathol 2012;65:604-7. [DOI: 10.1136/jclinpath-2012-200746] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
134 Alawawdeh A, Piantadosi C, Townsend AR, Karapetis CS, Padbury R, Roy AC, Moore J, Maddern G, Roder D, Smith A, Price TJ. Prognostic Differences of RAS Mutations: Results from the South Australian Metastatic Colorectal Registry. Target Oncol 2021. [PMID: 34822070 DOI: 10.1007/s11523-021-00856-9] [Reference Citation Analysis]
135 Breuer E, Hebeisen M, Schneider MA, Roth L, Pauli C, Frischer-Ordu K, Eden J, Pache B, Steffen T, Hübner M, Villeneuve L, Kepenekian V, Passot G, Gertsch P, Gupta A, Glehen O, Lehmann K. Site of Recurrence and Survival After Surgery for Colorectal Peritoneal Metastasis. J Natl Cancer Inst 2021;113:1027-35. [PMID: 33484560 DOI: 10.1093/jnci/djab001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 Saensa-ard S, Leuangwattanawanit S, Senggunprai L, Namwat N, Kongpetch S, Chamgramol Y, Loilome W, Khansaard W, Jusakul A, Prawan A, Pairojkul C, Khantikeo N, Yongvanit P, Kukongviriyapan V. Establishment of cholangiocarcinoma cell lines from patients in the endemic area of liver fluke infection in Thailand. Tumour Biol 2017;39:101042831772592. [DOI: 10.1177/1010428317725925] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
137 Chida K, Kotani D, Masuishi T, Kawakami T, Kawamoto Y, Kato K, Fushiki K, Sawada K, Kumanishi R, Shirasu H, Matsubara Y, Yuki S, Komatsu Y, Yamazaki K, Yoshino T. The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study. Oncologist 2021. [PMID: 34232546 DOI: 10.1002/onco.13870] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
138 Alniss HY. Thermodynamics of DNA Minor Groove Binders: Perspective. J Med Chem 2019;62:385-402. [DOI: 10.1021/acs.jmedchem.8b00233] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
139 Olmedillas-López S, Lévano-Linares DC, Alexandre CLA, Vega-Clemente L, Sánchez EL, Villagrasa A, Ruíz-Tovar J, García-Arranz M, García-Olmo D. Detection of KRAS G12D in colorectal cancer stool by droplet digital PCR. World J Gastroenterol 2017; 23(39): 7087-7097 [PMID: 29093617 DOI: 10.3748/wjg.v23.i39.7087] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
140 Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang K, Williams R, Wiezorek J. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol. 2013;31:759-765. [PMID: 23182985 DOI: 10.1200/jco.2012.45.1492] [Cited by in Crossref: 145] [Cited by in F6Publishing: 96] [Article Influence: 14.5] [Reference Citation Analysis]
141 Kriegl L, Vieth M, Kirchner T, Menssen A. Up-regulation of c-MYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer. Oncotarget 2012;3:1182-93. [PMID: 23045412 DOI: 10.18632/oncotarget.628] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 6.1] [Reference Citation Analysis]
142 Li ZZ, Wang F, Zhang ZC, Wang F, Zhao Q, Zhang DS, Wang FH, Wang ZQ, Luo HY, He MM, Wang DS, Jin Y, Ren C, Qiu MZ, Ren J, Pan ZZ, Li YH, Shao JY, Xu RH. Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response. Oncotarget 2016;7:28356-68. [PMID: 27050078 DOI: 10.18632/oncotarget.8541] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
143 Kim S. New and emerging factors in tumorigenesis: an overview. Cancer Manag Res 2015;7:225-39. [PMID: 26251629 DOI: 10.2147/CMAR.S47797] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
144 Ruiz-Bañobre J, Goel A. Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy. Adv Cancer Res 2021;151:231-304. [PMID: 34148615 DOI: 10.1016/bs.acr.2021.02.008] [Reference Citation Analysis]
145 Kim S, Yun YM, Chae HJ, Cho HJ, Ji M, Kim IS, Wee KA, Lee W, Song SH, Woo HI, Lee SY, Chun S. Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines. Ann Lab Med. 2017;37:180-193. [PMID: 28029011 DOI: 10.3343/alm.2017.37.2.180] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
146 Chung CH, Kim JH. One-step isothermal detection of multiple KRAS mutations by forming SNP specific hairpins on a gold nanoshell. Analyst 2018;143:3544-8. [PMID: 29687792 DOI: 10.1039/c8an00525g] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 Chen C, Chen C, Ho C, Chi W, Yeh C, Hu S, Friebe P, Palmer S, Huang C. Clinical Evaluation of IntelliPlex™ KRAS G12/13 Mutation Kit for Detection of KRAS Mutations in Codon 12 and 13: A Novel Multiplex Approach. Mol Diagn Ther 2019;23:645-56. [DOI: 10.1007/s40291-019-00418-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
148 Li Z, Buck M. Computational Design of Myristoylated Cell-Penetrating Peptides Targeting Oncogenic K-Ras.G12D at the Effector-Binding Membrane Interface. J Chem Inf Model 2020;60:306-15. [DOI: 10.1021/acs.jcim.9b00690] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
149 Lou E, Xiu J, Baca Y, Nelson AC, Weinberg BA, Beg MS, Salem ME, Lenz HJ, Philip P, El-Deiry WS, Korn WM. Expression of Immuno-Oncologic Biomarkers Is Enriched in Colorectal Cancers and Other Solid Tumors Harboring the A59T Variant of KRAS. Cells 2021;10:1275. [PMID: 34063999 DOI: 10.3390/cells10061275] [Reference Citation Analysis]
150 Bellon E, Ligtenberg MJ, Tejpar S, Cox K, de Hertogh G, de Stricker K, Edsjö A, Gorgoulis V, Höfler G, Jung A, Kotsinas A, Laurent-Puig P, López-Ríos F, Hansen TP, Rouleau E, Vandenberghe P, van Krieken JJ, Dequeker E. External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. Oncologist 2011;16:467-78. [PMID: 21441573 DOI: 10.1634/theoncologist.2010-0429] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 6.5] [Reference Citation Analysis]
151 Kubicka S, Greil R, André T, Bennouna J, Sastre J, Van Cutsem E, von Moos R, Osterlund P, Reyes-Rivera I, Müller T, Makrutzki M, Arnold D; ML18147 study investigators including AIO, GERCOR, FFCD, UNICANCER GI, TTD, BGDO, GEMCAD, and AGMT groups. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Ann Oncol 2013;24:2342-9. [PMID: 23852309 DOI: 10.1093/annonc/mdt231] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 6.7] [Reference Citation Analysis]
152 Anderson SM. Laboratory methods for KRAS mutation analysis. Expert Rev Mol Diagn 2011;11:635-42. [PMID: 21745016 DOI: 10.1586/erm.11.42] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
153 Panaccione A, Zhang Y, Mi Y, Mitani Y, Yan G, Prasad ML, McDonald WH, El-Naggar AK, Yarbrough WG, Ivanov SV. Chromosomal abnormalities and molecular landscape of metastasizing mucinous salivary adenocarcinoma. Oral Oncol 2017;66:38-45. [PMID: 28249646 DOI: 10.1016/j.oraloncology.2016.12.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
154 Heublein S, Grasse K, Hessel H, Burges A, Lenhard M, Engel J, Kirchner T, Jeschke U, Mayr D. KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants. BMC Cancer 2013;13:483. [PMID: 24139521 DOI: 10.1186/1471-2407-13-483] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
155 Zhu X, Li J, He H, Huang M, Zhang X, Wang S. Application of nanomaterials in the bioanalytical detection of disease-related genes. Biosens Bioelectron 2015;74:113-33. [PMID: 26134290 DOI: 10.1016/j.bios.2015.04.069] [Cited by in Crossref: 57] [Cited by in F6Publishing: 44] [Article Influence: 8.1] [Reference Citation Analysis]
156 Niu W, Wang G, Feng J, Li Z, Li C, Shan B. Correlation between microsatellite instability and RAS gene mutation and stage III colorectal cancer. Oncol Lett 2019;17:332-8. [PMID: 30655771 DOI: 10.3892/ol.2018.9611] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
157 Zhang SY, Zhang SQ, Nagaraju GP, El-rayes BF. Biomarkers for personalized medicine in GI cancers. Molecular Aspects of Medicine 2015;45:14-27. [DOI: 10.1016/j.mam.2015.06.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
158 Yari A, Afzali A, Aalipour M, Nakheai M, Zahedi MJ. KRAS and BRAF mutations in Iranian colorectal cancer patients: A systematic review and meta-analysis. Caspian J Intern Med 2020;11:355-69. [PMID: 33680376 DOI: 10.22088/cjim.11.4.355] [Reference Citation Analysis]
159 Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, Taylor BS, Chitale D, Halilovic E, Wilson M, Huberman K, Ricarte Filho JC. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res. 2010;70:5901-5911. [PMID: 20570890 DOI: 10.1158/0008-5472.can-10-0192] [Cited by in Crossref: 187] [Cited by in F6Publishing: 132] [Article Influence: 15.6] [Reference Citation Analysis]
160 Rehman AH, Jones RP, Poston G. Prognostic and predictive markers in liver limited stage IV colorectal cancer. Eur J Surg Oncol 2019;45:2251-6. [PMID: 31279594 DOI: 10.1016/j.ejso.2019.06.038] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
161 Uprety D, Adjei AA. KRAS: From undruggable to a druggable Cancer Target. Cancer Treatment Reviews 2020;89:102070. [DOI: 10.1016/j.ctrv.2020.102070] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
162 Chow L, Lin P, Chang JS, Chu P, Lee P, Chen S, Cheng Y, Lee J, Chang J, Liu T. Differences in the frequencies of K-ras c12-13 genotypes by gender and pathologic phenotypes in colorectal tumors measured using the allele discrimination method. Environ Mol Mutagen 2012;53:22-31. [DOI: 10.1002/em.20673] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
163 Milton AV, Konrad DB. Epithelial-mesenchymal transition and H2O2 signaling - a driver of disease progression and a vulnerability in cancers. Biol Chem 2022. [PMID: 35032422 DOI: 10.1515/hsz-2021-0341] [Reference Citation Analysis]
164 Ličar A, Cerkovnik P, Novaković S. Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer. Med Oncol 2011;28:1048-53. [PMID: 20645028 DOI: 10.1007/s12032-010-9631-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
165 Schleifman EB, Tam R, Patel R, Tsan A, Sumiyoshi T, Fu L, Desai R, Schoenbrunner N, Myers TW, Bauer K, Smith E, Raja R. Next generation MUT-MAP, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panel. PLoS One 2014;9:e90761. [PMID: 24658394 DOI: 10.1371/journal.pone.0090761] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
166 Lugli A, Zlobec I. Gene Signatures in Colorectal Cancer. In: Russo A, Iacobelli S, Iovanna J, editors. Diagnostic, Prognostic and Therapeutic Value of Gene Signatures. Totowa: Humana Press; 2012. pp. 115-36. [DOI: 10.1007/978-1-61779-358-5_8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
167 Tan C, Du X. KRAS mutation testing in metastatic colorectal cancer. World J Gastroenterol 2012; 18(37): 5171-5180 [PMID: 23066310 DOI: 10.3748/wjg.v18.i37.5171] [Cited by in F6Publishing: 73] [Reference Citation Analysis]
168 Vignot S, Besse B, André F, Spano JP, Soria JC. Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers. Crit Rev Oncol Hematol 2012;84:301-13. [PMID: 22710198 DOI: 10.1016/j.critrevonc.2012.05.002] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 5.6] [Reference Citation Analysis]
169 Bikov KA, Mullins CD, Hung A, Seal B, Onukwugha E, Hanna N. Patterns of Biologics Use Across Treatment Lines in Elderly (Age >65) Medicare Patients With Metastatic Colon Cancer. Oncologist 2016;21:676-83. [PMID: 27125751 DOI: 10.1634/theoncologist.2015-0199] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
170 Peacock JD, Dykema KJ, Toriello HV, Mooney MR, Scholten DJ, Winn ME, Borgman A, Duesbery NS, Hiemenga JA, Liu C, Campbell S, Nickoloff BP, Williams BO, Steensma M. Oculoectodermal syndrome is a mosaic RASopathy associated with KRAS alterations. Am J Med Genet 2015;167:1429-35. [DOI: 10.1002/ajmg.a.37048] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
171 Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Ramalingam SS, Burns TF, Meric-Bernstam F, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Friberg G, Lito P, Govindan R, Li BT. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med 2020;383:1207-17. [PMID: 32955176 DOI: 10.1056/NEJMoa1917239] [Cited by in Crossref: 203] [Cited by in F6Publishing: 121] [Article Influence: 101.5] [Reference Citation Analysis]
172 Charitou T, Srihari S, Lynn MA, Jarboui MA, Fasterius E, Moldovan M, Shirasawa S, Tsunoda T, Ueffing M, Xie J, Xin J, Wang X, Proud CG, Boldt K, Al-Khalili Szigyarto C, Kolch W, Lynn DJ. Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRASG13D mutation. Br J Cancer 2019;121:37-50. [PMID: 31133691 DOI: 10.1038/s41416-019-0477-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
173 Yang M, Xiao X, Xing X, Li X, Xia T, Long H. KRAS and VEGF gene 3'-UTR single nucleotide polymorphisms predicted susceptibility in colorectal cancer. PLoS One 2017;12:e0174140. [PMID: 28328959 DOI: 10.1371/journal.pone.0174140] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
174 Zanatto RM, Santos G, Oliveira JC, Pracucho EM, Nunes AJF, Lopes-Filho GJ, Saad SS. IMPACT OF KRAS MUTATIONS IN CLINICAL FEATURES IN COLORECTAL CANCER. Arq Bras Cir Dig 2020;33:e1524. [PMID: 33331426 DOI: 10.1590/0102-672020200003e1524] [Reference Citation Analysis]
175 Gerber H, Sibener LV, Lee LJ, Gee M. Intracellular targets as source for cleaner targets for the treatment of solid tumors. Biochemical Pharmacology 2019;168:275-84. [DOI: 10.1016/j.bcp.2019.07.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
176 Malapelle U, Carlomagno C, de Luca C, Bellevicine C, Troncone G. KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond. J Clin Pathol 2013;67:1-9. [DOI: 10.1136/jclinpath-2013-201835] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
177 Savonarola A, Palmirotta R, Guadagni F, Silvestris F. Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy. Pharmacogenomics J 2012;12:277-86. [PMID: 22760589 DOI: 10.1038/tpj.2012.28] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
178 Mathai RA, Vidya RVS, Reddy BS, Thomas L, Udupa K, Kolesar J, Rao M. Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision Oncology. J Clin Med 2019;8:E373. [PMID: 30889786 DOI: 10.3390/jcm8030373] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 15.0] [Reference Citation Analysis]
179 Macarulla T, Cervantes A, Tabernero J, Roselló S, Van Cutsem E, Tejpar S, Prenen H, Martinelli E, Troiani T, Laffranchi B, Jego V, von Richter O, Ciardiello F. Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer. Br J Cancer 2015;112:1874-81. [PMID: 25989270 DOI: 10.1038/bjc.2015.144] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
180 Zhang X, Dong Z, Cui H. Interplay between Epigenetics and Cellular Metabolism in Colorectal Cancer. Biomolecules 2021;11:1406. [PMID: 34680038 DOI: 10.3390/biom11101406] [Reference Citation Analysis]
181 Henry JT, Coker O, Chowdhury S, Shen JP, Morris VK, Dasari A, Raghav K, Nusrat M, Kee B, Parseghian C, Pant S, Jeyakumar N, Zhu L, Nishioka Y, Fogelman D, Wolff RA, Hong D, Overman MJ, Vauthey J, Kopetz S, Johnson B. Comprehensive Clinical and Molecular Characterization of KRAS G12C-Mutant Colorectal Cancer. JCO Precis Oncol 2021;5:PO. [PMID: 34250391 DOI: 10.1200/PO.20.00256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Malki A, ElRuz RA, Gupta I, Allouch A, Vranic S, Al Moustafa AE. Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements. Int J Mol Sci 2020;22:E130. [PMID: 33374459 DOI: 10.3390/ijms22010130] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
183 Yu S, Xiao X, Lu J, Qian X, Liu B, Feng J. Colorectal cancer patients with low abundance of KRAS mutation may benefit from EGFR antibody therapy. PLoS One. 2013;8:e68022. [PMID: 23874486 DOI: 10.1371/journal.pone.0068022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
184 Nagayama S, Low SK, Kiyotani K, Nakamura Y. Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy. Cancers (Basel) 2021;13:4803. [PMID: 34638288 DOI: 10.3390/cancers13194803] [Reference Citation Analysis]